MicroRNA Expression Analysis for Thyroid Lesion Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing thyroid nodules, particularly indeterminate lesions, are inadequate as they often fail to accurately distinguish between benign and malignant lesions, leading to unnecessary surgeries and diagnostic uncertainties.
Innovation Solution
The use of microRNA expression analysis, specifically evaluating mir-328, mir-222, mir-197, mir-181a, mir-146b, and mir-21 RNA levels in thyroid tissue samples, to create a predictive model that differentiates between malignant and benign thyroid lesions through statistical analysis and machine learning algorithms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fine needle aspiration with cytopathological evaluation is used to assess thyroid nodules, then the diagnostic process is non-invasive and easy to perform, but the measurement precision is insufficient for indeterminate lesions
Solution Approach 1:
The patent transitions from cytopathological evaluation to molecular analysis by measuring microRNA expression levels. This parameter change from cellular morphology to molecular biomarker quantification enables accurate differentiation of indeterminate thyroid lesions, resolving the measurement precision limitation while maintaining the non-invasive nature of fine needle aspiration.
2Reliability
If hemi-thyroidectomy or total thyroidectomy is performed for indeterminate lesions, then definitive diagnosis is achieved, but unnecessary surgeries are performed when lesions are benign
Solution Approach 1:
The patent performs preliminary molecular testing of microRNA expression levels on fine needle aspiration samples before recommending surgery. This preliminary action provides definitive diagnostic information that can prevent unnecessary thyroidectomies for benign lesions while identifying malignant cases requiring surgical intervention, thus eliminating the need for exploratory surgery.
Solution Approach 2:
The patent introduces microRNA expression analysis as an intermediary diagnostic step between fine needle aspiration and thyroidectomy. This molecular biomarker assessment serves as a mediator that provides definitive diagnosis without requiring surgical intervention, thereby preventing harmful unnecessary surgeries while maintaining reliable diagnosis.
3Measurement precision
If multiple microRNA markers are analyzed to improve diagnostic accuracy, then the measurement precision increases, but the device complexity and analysis time increase
Solution Approach 1:
The patent employs a multi-functional diagnostic approach that analyzes multiple microRNA markers (miR-222, miR-328, miR-197, and miR-21) simultaneously using a single quantitative RT-PCR platform. This universal system handles multiple biomarkers through one integrated assay, achieving high measurement precision for thyroid lesion classification without proportionally increasing device complexity.
Data Source
AI summary
The application describes methods for accurately evaluating whether thyroid test samples, especially indeterminate thyroid samples, are benign or malignant.